Research Reports

Immune Repertoire Sequencing Market Size to Increase by US$ 114.3 million during 2018-2026 | Forecasting Strategies

Published by Coherent Market Insights

Posted on September 15, 2021

3 min read

· Last updated: February 10, 2026

Add as preferred source on Google
Thames Water financial restructuring proposal amidst Class B creditor dispute - Global Banking & Finance Review
This image illustrates the financial challenges faced by Thames Water, including its restructuring efforts and the conflict with Class B creditors. The article discusses how the utility company aims to stabilize its finances amid competing plans.

Immune Repertoire Sequencing Market Expected to Grow by $114.3 Million

Global Immune Repertoire Sequencing Market, By Product Type (Instruments and Assay Kits (B-Cell Receptor Kits and T-Cell Receptor Kits)), By Application (Infectious Diseases, Cancer Immunotherapy, Vaccine Development & Efficacy, Autoimmune Diseases, Biomarker Discovery, and Transplant Rejection & Tolerance), By End User (Academic & Research Institutes, Diagnostic Labs, and Pharmaceutical & Biotechnology Companies), and By Geography (North America, Asia Pacific, Latin America, Europe, Middle East, and Africa), is projected to attain a market valuation of US$ XX million in 2021 and is anticipated to grow at a CAGR of XX% during the forecast period (2021-2028), as mentioned in a new report published by Coherent Market Insights.

Request for a Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/1517

Overview

The promising methodology for analyzing human immune repertoire is DNA fingerprinting. The method is based on tandem duplication of DNA molecules between highly informative probes that directly capture the genetic variation. Multiple measurements of such parameters as heterozygosis, homozygosis, frequency of tandem duplication, and others are used to determine genetic differences among humans. This method relies on highly sensitive and molecular probes such as cytogenetics, transcriptomics, RSN typing and others. The results are comparable with those of whole genome sequencing methods. Moreover, this technique can be used to study the complex genetic interactions between humans.

Competitive Landscape

Major companies contributing in the global immune repertoire sequencing market include Thermo Fisher Scientific, Roche Holding, CD Genomics, Junom Therapeutics, ArcherDX, Adaptive Biotechnologies, Atreca, Illumina, and Pacific Biosciences.

Drivers

Growing penetration of advanced immune repertoire sequencing methodology in personalized immune alteration procedures is expected to propel growth of the immune repertoire sequencing market during the forecast period.

Moreover, increasing application of immune repertoire sequencing in the treatment of cancer, allergies, biomarkers development, and others combined with the increased volume of product launches is expected to augment growth of the immune repertoire sequencing market throughout the forecast period.

The Epitome of the COVID-19 Aftermath

The global immune repertoire sequencing market has witnessed moderate growth due to the ongoing COVID-19 prevalence. The one-year, ten-month old virus has raised the demand and awareness among people over the significance of immunity-boosters. The infected people suffered from weakness in their immune systems, thus, catalyzing the demand for immunotherapies.

Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/1517

Key Takeaways

  • The immune repertoire sequencing market is anticipated to grow at a CAGR of XX % during the forecast period owing to the advent of advanced sequencing methods and increasing number of product launches. For instance, in August 2021, the Centers for Commercialization of Cancer Immunotherapy (C3i) report that immunotherapies will account for 60% of overall cancer treatments by 2025.

  • From the geographical standpoint, the North American region is poised to accelerate the expansion of the immune repertoire sequencing market on the heels of increased adoption of immunotherapy in treating infectious diseases and cancer.

  • Another noteworthy geographic region is Europe, which is catalyzed by increasing expenditure of R&D activities aimed at developing immune repertoire sequencing solutions.

Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1517

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

The post Immune Repertoire Sequencing Market Size to Increase by US$ 114.3 million during 2018-2026 | Forecasting Strategies appeared first on Gatorledger.

Frequently Asked Questions

What is the expected growth of the immune repertoire sequencing market?
The immune repertoire sequencing market is anticipated to grow by US$ 114.3 million during the forecast period from 2018 to 2026.
What are the main drivers for the market's growth?
Key drivers include the increasing application of immune repertoire sequencing in cancer treatment and personalized medicine, as well as advancements in sequencing methods.
Which regions are expected to see significant market expansion?
North America is expected to lead the market expansion due to higher adoption of immunotherapy, while Europe is also notable for its increased R&D expenditures.
What companies are key players in the immune repertoire sequencing market?
Major companies include Thermo Fisher Scientific, Roche Holding, CD Genomics, and Adaptive Biotechnologies, among others.
How has COVID-19 impacted the immune repertoire sequencing market?
The ongoing COVID-19 pandemic has raised awareness and demand for immune repertoire sequencing, contributing to moderate growth in the market.

Tags

Related Articles

More from Research Reports

Explore more articles in the Research Reports category